🇺🇸 FDA
Patent

US 7678824

Methods for treatment with bucindolol based on genetic targeting

granted A61PA61P25/06A61P25/22

Quick answer

US patent 7678824 (Methods for treatment with bucindolol based on genetic targeting) held by The Regents of the University of Colorado, a Body Corporate expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Mar 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P25/06, A61P25/22, A61P35/00, A61P43/00